Submitted by Anonymous (not verified) on 21 November 2023 - 11:12
Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Multiple Myeloma, Date of authorisation: 21/11/2016, Revision: 17, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Multiple Myeloma, Date of authorisation: 21/11/2016, Revision: 17, Status: Authorised